Introduction {#Sec1}
============

Asthma is a chronic inflammatory airway disease characterized by airway hyper-responsiveness, bronchoconstriction, airway edema, and mucus plugging. Approximately 5--10% of patients with asthma remain uncontrolled despite receiving the maximum recommended treatment. These patients are at increased risk of frequent and severe exacerbations, have impaired lung function and impaired quality of life, and account for a high healthcare cost burden \[[@CR1]\]. As such, they represent a population with unmet needs, for whom new treatments are required.

Asthma phenotypes, including inflammatory, clinical, and trigger-related subtypes, have been identified and defined by interactions between genetic and environmental factors \[[@CR2]--[@CR5]\]. Type 2-high asthma is a common subtype, characterized by the release of the inflammatory prototypical cytokines interleukin (IL)-4, IL-5, and IL-13 from immune cells \[[@CR6]\]. Several biomarkers are linked to type 2 airway inflammation, including fractional exhaled nitric oxide (FeNO), serum immunoglobulin E (IgE), periostin, and blood and sputum eosinophils \[[@CR5]\]. Identification of inflammatory pathways involved in asthma pathophysiology has produced therapeutic approaches to severe asthma that target type 2 inflammatory mediators, including antibodies directed at IL-5, a key cytokine involved in eosinophil proliferation and recruitment to sites of inflammation.

Dupilumab is a fully human monoclonal antibody (mAb) directed against IL-4 receptor alpha (IL-4Rα). Dupilumab inhibits signaling of IL-4 and IL-13, cytokines that are key drivers of type 2 immune diseases (e.g. atopic/allergic diseases) such as atopic dermatitis (AD), asthma, allergic rhinitis, chronic rhinosinusitis (with or without nasal polyps), and food allergies that are often associated as comorbidities \[[@CR7]\]. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled moderate-to-severe AD.

In a phase 2a proof-of-concept study, dupilumab added to medium-to-high-dose inhaled corticosteroids (ICS) plus a long-acting β~2~-agonist (LABA) in patients with uncontrolled persistent eosinophilic asthma \[[@CR8]\] significantly reduced the number of patients with asthma exacerbation by 87% and improved lung function compared to placebo. Given these promising findings, a phase 2b dose-ranging study assessed dupilumab as add-on therapy in a patient population including both eosinophilic and non-eosinophilic patients. Dupilumab was well tolerated, and doses given every 2 weeks improved lung function (least squares \[LS\] mean change in forced expiratory volume in 1 s \[FEV~1~\] from baseline to week 12 of 0.31 and 0.28 L for 200 and 300 mg of dupilumab, respectively, and 0.12 L for placebo), reduced severe exacerbations (70.0% to 70.5% risk reduction vs. placebo), improved asthma control (LS mean change in the 5-item asthma control questionnaire \[ACQ-5\] score from baseline to week 24 of − 1.49 and − 1.45 for 200 and 300 mg of dupilumab, respectively, and − 1.14 for placebo) \[[@CR9]\], and reduced levels of type 2 inflammatory biomarkers including FeNO (LS mean change − 18.69 and − 20.86 ppb for 200 and 300 mg doses, respectively, and − 3.90 ppb for placebo), plasma eotaxin-3 (− 32.45 and − 30.63 pg/mL in dupilumab doses, − 1.84 pg/mL in placebo), and serum IgE (− 235.40 and − 207.95 IU/mL in dupilumab doses, 6.21 IU/mL increase in placebo) over a 24-week treatment period. While this study established that a 2-weekly dosing regimen was optimum, it did not establish the most appropriate dose \[[@CR9]\].

Following positive phase 2 results, a phase 3 program was initiated with the objective of providing further evidence of the efficacy and safety of dupilumab in patients with uncontrolled, moderate-to-severe asthma.

Methods {#Sec2}
=======

Liberty Asthma QUEST Study Design {#Sec3}
---------------------------------

QUEST is a phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with uncontrolled, moderate-to-severe asthma who are receiving continuous treatment with ICS plus one or two other asthma controller medicines (Clinical Trials.gov Identifier: NCT02414854). Database lock was planned to have data on the 52-week treatment period of at least 1638 randomized patients. Patients were randomized at 413 sites in 22 countries globally, making QUEST the largest placebo-controlled study ever performed to date in uncontrolled persistent asthma with a biologic agent. Subsequent to the findings of the phase 2b study that dupilumab was effective for patients with eosinophilic and non-eosinophilic asthma, the primary enrolled patient population in QUEST was based on clinical criteria alone, without any pre-specified biomarker requirement (an upper baseline blood eosinophil count limit of \> 1500/µL was included). This enabled a full, unbiased analysis of the influence of baseline biomarker and clinical characteristics on treatment response. The key inclusion and exclusion criteria for QUEST are listed in Table [1](#Tab1){ref-type="table"}.Table 1Patient eligibility criteria**Key inclusion criteria**Adults and adolescent pts (≥ 12 years)Physician-diagnosed asthma for ≥ 12 months, based on GINA 2017 Guidelines \[[@CR23]\]Existing treatment with medium-to-high-dose ICS (≥ 250 μg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 μg/day of fluticasone propionate or equivalent) in combination with a second controller (e.g., LABA, LTRA) for at least 3 months with a stable dose ≥ 1 month prior to visit 1Pre-bronchodilator FEV~1~ ≤ 80% of predicted normal for adults and ≤ 90% of predicted normal for adolescents at visits 1 and 2, prior to randomizationACQ-5 score ≥ 1.5 at visits 1 and 2, prior to randomizationReversibility of at least 12% and 200 mL in FEV~1~ after the administration of 200--400 μg albuterol/salbutamol or levalbuterol/levosalbutamol before randomizationMust have experienced, within 1 year prior to visit 1, any of the following events: Treatment with a systemic steroid (oral or parenteral) for worsening asthma at least once Hospitalization or emergency medical care visit for worsening asthma**Key exclusion criteria**Pts \< 12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higherWeight is less than 30 kgDiagnosis of chronic obstructive pulmonary disease or other lung disease that may impair lung functionEvidence of lung disease(s) other than asthma, either clinical evidence or imaging (e.g., chest X-ray, CT, MRI), within 12 months of visit 1 as per local standard of careA severe asthma exacerbation at any time from 1 month before screening up to and including the baseline visitCurrent smokers, or smokers who stopped within 6 months before screening or had a previous smoking history of \> 10 pack-yearsAnti-IgE therapy within 130 days before screening or any other biologic therapy/immunosuppressant within 2 months (or five half-lives) before screeningExposure to another investigative antibody within five half-lives or 6 months before screening, or to any other (non-antibody) investigative agent within 30 days before screeningComorbid disease that might interfere with the evaluation of dupilumabPrevious treatment with dupilumab*ACQ*-*5* Asthma Control Questionnaire 5-question version, *CT* computed tomography, *FEV*~*1*~ forced expiratory volume in 1 s, *ICS* inhaled corticosteroid, *LABA* long-acting β~2~-agonist, *LTRA* leukotriene receptor antagonists, *MRI* magnetic resonance imaging, *pts* patients

The study consisted of three periods: a 4 ± 1-week screening period, a 52-week randomized treatment period, and a 12-week post-treatment follow-up period (unless patients entered an open-label extension study) (Fig. [1](#Fig1){ref-type="fig"}). Patient eligibility and level of asthma control were established during the screening period. The study was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc., and conducted in accordance with the principles established in the Declaration of Helsinki and the International Conference on Harmonization guidelines for good clinical practice. All study documents and procedures were approved by the appropriate institutional review board/ethics committees at each study site, and written informed consent was obtained from all patients before initiation into the study.Fig. 1LIBERTY Asthma QUEST study design.*IP* investigational product, *q2w* every 2 weeks, *sc* subcutaneously

Treatment/Dosing {#Sec4}
----------------

A total of 1902 patients (≥ 12 years) were randomized in a 2:2:1:1 ratio to receive 52 weeks of add-on therapy with subcutaneously administered dupilumab 200 mg (loading dose 400 mg) or 300 mg (loading dose 600 mg) every 2 weeks (q2w), or matched placebo corresponding to the respective volumes of each dupilumab pre-filled syringe (1.14 and 2 mL for the 200 and 300 mg doses, respectively). Hence, approximately 634 patients for each dupilumab dose group and 317 patients for each matching placebo group were randomized.

Patients were stratified at randomization by age (\< 18, ≥ 18 years), blood eosinophil count at screening (\< 300, ≥ 300 cells/μL), baseline ICS dose (medium versus high), and country. For the duration of the study, all patients continued to receive their prescribed ICS plus up to two additional asthma controller medications, without change. Throughout the study, patients were permitted to use a short-acting β~2~-adrenergic receptor agonist (either salbutamol or levosalbutamol) as relief medication for asthma symptoms as needed.

Objectives and Outcome Measures {#Sec5}
-------------------------------

A summary of the study outcome measures is provided in Table [2](#Tab2){ref-type="table"}. The two primary efficacy endpoints were annualized rate of severe exacerbation events during the 52-week treatment period and absolute change from baseline in pre-bronchodilator FEV~1~ at week 12. A severe asthma exacerbation was defined as a deterioration of asthma requiring treatment for ≥ 3 days with systemic corticosteroids, or hospitalization or an emergency room visit because of asthma, requiring systemic corticosteroids. The key secondary endpoint was the percentage change from baseline to week 12 in pre-bronchodilator FEV~1~. Additional lung function assessments throughout the study were the percentage predicted FEV~1~, morning/evening peak expiratory flow (measured at home using an electronic peak flow meter), forced vital capacity, forced expiratory flow 25--75%, post-bronchodilator FEV~1~, and post-bronchodilator slope analysis on FEV~1~ to characterize the loss of lung function. Patient-reported outcome measures of asthma control (ACQ-5) and quality of life, including the asthma quality of life questionnaire (AQLQ), were assessed throughout the study period. Safety and tolerability were evaluated by assessing the incidence of adverse events (AEs) and serious AEs, and by examination of vital signs and physical assessment, clinical laboratory testing, and 12-lead electrocardiography (ECG). Blood samples for exploratory genetic analysis of DNA/RNA were also collected and stored for future investigation.Table 2Summary of study outcome measuresOutcome measureTime frame**Primary efficacy endpoints**Annualized rate of severe exacerbation events52 weeksAbsolute change from baseline in pre-bronchodilator FEV~1~Week 12**Secondary efficacy endpoints**Percentage change from baseline in pre-bronchodilator FEV~1~^a^Week 12Annualized rate of severe exacerbation events in pts with ≥ 300 or ≥ 150 eosinophils/μLWeek 12Absolute change from baseline in pre-bronchodilator FEV~1~ in pts with ≥ 300 or ≥ 150 eosinophils/μLWeek 12Absolute change from baseline in pre-bronchodilator FEV~1~Weeks 2, 4, 8, 24, 36, 52Percentage change from baseline in pre-bronchodilator FEV~1~Weeks 2, 4, 8, 24, 36, 52Annualized rate of severe exacerbation events in pts with ≥ 300 eosinophils/μL52 weeksAbsolute change from baseline in pre-bronchodilator FEV~1~ in pts with ≥ 300 eosinophils/μLWeek 12Percentage change from baseline in pre-bronchodilator FEV~1~ in pts with ≥ 300 eosinophils/μLWeek 12Annualized rate of severe exacerbation events in pts with ≥ 150 eosinophils/μL52 weeksAbsolute change from baseline in pre-bronchodilator FEV~1~ in pts with ≥ 150 eosinophils/μLWeek 12Percentage change from baseline in pre-bronchodilator FEV~1~ in pts with ≥ 150 eosinophils/μLWeek 12Annualized rate of severe exacerbation events in pts on high-dose ICS52 weeksAbsolute change from baseline in pre-bronchodilator FEV~1~ in pts on high-dose ICSWeek 12Percentage change from baseline in pre-bronchodilator FEV~1~ in pts on high-dose ICSWeek 12Change from baseline in other lung function measurements^b^Weeks 2, 4, 8, 12, 24, 36, 52Annualized rate of loss of asthma control event52 weeksAnnualized rate of severe exacerbation events resulting in hospitalization or ER visit52 weeksTime to first severe exacerbation event52 weeksTime to first loss of asthma control event52 weeksChange from baseline in ACQ-5 and ACQ-7 scoreWeeks 2, 4, 8, 12, 24, 36, 52Change from baseline in am/pm asthma symptom score and nocturnal awakeningsWeeks 2, 4, 8, 12, 24, 36, 52Change from baseline in rescue medication useWeeks 2, 4, 8, 12, 24, 36, 52Change from baseline in healthcare resource utilizationWeeks 12, 24, 36, 52Change from baseline in PROs (AQLQ, EQ-5D-5L, HADS, SNOT-22^c^, RQLQ^d^)Weeks 12, 24, 36, 52**Other endpoints**Systemic drug concentration and anti-drug antibodiesWeeks 12, 24, 36, 52Biomarker assessment (FeNO, blood eosinophils, periostin, TARC, IgE, ECP, eotaxin-3)Weeks 12, 24, 36, 52Safety and tolerability (includes AEs, vital signs, physical exam, clinical labs, ECG)Continuous*ACQ*-*5* Asthma Control Questionnaire 5-question version, *ACQ*-*7* Asthma Control Questionnaire 7-question version, *AE* adverse event, *AQLQ (S)* Asthma Quality Of Life Questionnaire with Standardized Activities, *CRS* chronic rhinosinusitis, *CRSwNP* chronic rhinosinusitis with nasal polyposis, *ECG* eletrocardiogram, *ECP* eosinophil cationic protein, *EQ*-*5D*-*5L* European Quality of Life Working Group Health Status Measure 5 Dimensions--5 Levels, *ER* emergency room, *FEF* forced expiratory flow, *FeNO* exhaled nitric oxide, *FEV*~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *HADS* Hospital Anxiety and Depression Scale, *ICS* inhaled corticosteroid, *PEF* peak expiratory flow, *PRO* patient-reported outcome, *pts* patients, *RQLQ* Rhinoconjunctivitis Quality of Life Questionnaire, *SNOT*-*22* 22-item Sino Nasal Outcome Test, *TARC* thymus and activation-regulated chemokine^a^Key secondary endpoint^b^Percentage predicted FEV~1~, morning/evening PEF, FVC, FEF~25--75%~, post-bronchodilator FEV~1~^c^Only in pts with CRS/CRSwNP^d^Only in pts with allergic rhinitis

Statistical Considerations {#Sec6}
--------------------------

Efficacy analyses were performed on the intention-to-treat (ITT) population (defined as all randomized patients according to the treatment allocated), regardless of whether treatment was received. The annualized rate of severe exacerbation events was analyzed using a negative binomial regression model, with the total number of events occurring during the 52-week treatment period as the response variable, and the four treatment groups, age, region (pooled country), baseline eosinophil strata, baseline ICS dose level, and number of severe exacerbation events within 1 year prior to the study as covariates. Log-transformed observation duration was the offset variable.

Patients who discontinued the study medication were encouraged to return to the clinic for all remaining study visits, and all severe exacerbation events that happened up to week 52 were included in the primary analysis, regardless of whether or not the patient was receiving treatment.

Change from baseline in continuous endpoints such as FEV~1~ and patient-reported outcomes were analyzed using a mixed-effects model with repeated measures (MMRM). The model included changes from baseline values as response variables, and treatment, age, baseline eosinophil strata, baseline ICS dose level, visit, treatment-by-visit interaction, baseline value, and baseline-by-visit interaction as covariates. In addition, sex and baseline height were included as covariates only in the models for spirometry parameters. For patients who discontinued the study treatment and stayed in the study, off-treatment measurements were included in the primary model. An unstructured correlation matrix was used to model within-patient errors, and parameters were estimated using the restricted maximum likelihood method with the Newton--Raphson algorithm.

For subgroups defined in Table [3](#Tab3){ref-type="table"}, treatment-by-subgroup interactions were analyzed using a negative binomial model/MMRM similar to the primary model, with subgroup and treatment-by-subgroup interaction added as covariates in the negative binomial models and subgroup, subgroup-by-treatment interaction, and subgroup-by-treatment-by-visit interaction added as covariates in the MMRM models. Summary statistics were also provided within each subgroup. Planned subgroups for analysis are listed in Table [3](#Tab3){ref-type="table"}, including subgroups defined by baseline blood eosinophil counts, and by baseline FeNO and baseline periostin levels.Table 3Patient subgroups for analysisSubgroupCriteriaAge group (years)\< 18, 18--64, ≥ 65; \< 18, ≥ 18GenderMale, femaleRegionAsia: Japan, South Korea, and Taiwan; Latin America: Argentina, Brazil, Colombia, Chile, and Mexico; East Europe: Hungary, Poland, Russia, Turkey, and Ukraine; Western countries: Australia, Canada, France, Germany, Italy, South Africa, Spain, UK, and USATerritoryNorth America: Canada and USA; European Union: France, Germany, Hungary, Italy, Poland, Spain, and UK; Rest of world: Argentina, Australia, Brazil, Colombia, Chile, Japan, Mexico, Russia, South Africa, South Korea, Taiwan, Turkey, and UkraineRace/ethnicityCaucasian/White, Black/of African descent, Asian/Oriental, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, OtherBaseline blood eosinophil level (cells/μL)≥ 300, \< 300; ≥ 150, \< 150Background ICS dose levels at randomizationMedium, highBackground controller type at randomizationICS and LABA only, ICS and LABA and anti-leukotrienes only; ICS, LABA, and any third controller, otherBaseline FEV~1~ (L)≤ 1.75, \> 1.75ACQ-5≤ 2, \> 2Number of severe asthma exacerbations prior to the study1, \> 1Baseline weight (kg)\< 60, ≥ 60, \< 70, ≥ 70, \< 90, ≥ 90Baseline BMI (kg/m^2^)\< 25, 25 to \< 30, ≥ 30Smoking historyFormer, neverAtopic medical conditionYes, noAge at onset of asthma (years)\< 18, 18--40, \> 40Baseline predicted FEV~1~ (%)\< 60, 60--90Baseline periostin (ng/mL)\< Median, ≥ medianBaseline FeNO (ppb)\< 25, ≥ 25 to \< 50, ≥ 50*ACQ*-*5* Asthma Control Questionnaire 5-question version, *BMI* body mass index, *FeNO* exhaled nitric oxide, *FEV*~*1*~ forced expiratory volume in 1 s, *ICS* inhaled corticosteroids, *LABA* long-acting β~2~-agonist

Time-to-event endpoints were analyzed using a Cox regression model, with time to event as the dependent variable and treatment, age, number of asthma exacerbation events in the previous year, region (pooled country), baseline eosinophil strata, and baseline ICS dose level as covariates. The Kaplan--Meier method was used to estimate the probability of a patient experiencing an event.

Descriptive statistics were used for demographic and clinical characteristics, pharmacodynamic variables, and for safety variables including AEs, vital signs and findings on physical examination, clinical laboratory testing, and ECG.

Sample Size Estimates {#Sec7}
---------------------

Assuming an annualized exacerbation rate in the placebo group of 0.6, a sample size of approximately 1638 patients was estimated to provide 99% power (two-tailed α level of 0.05) to detect a 55% relative risk reduction (i.e., annualized rate of 0.27 for the dupilumab group) in the annualized rate of severe exacerbations. This sample size was also expected to provide 98% power to the second primary endpoint, capable of detecting a treatment difference of 0.15 L in change of FEV~1~ from baseline to week 12. In a population of this size, approximately 84 adolescent patients and 690 (42%) patients with a baseline blood eosinophil count of ≥ 300 cells/μL were expected to be randomized.

Discussion {#Sec8}
==========

Moderate-to-severe asthma patients with persistent symptoms despite ICS plus LABA use represent a population of significant unmet need and one for whom new treatments are required. These patients are at high risk of asthma exacerbations and a substantial proportion has a history of life-threatening asthma attacks. Patients with severe asthma face an accelerated decline in lung function, which often impairs quality of life and interferes with their work and/or their daily activities. QUEST examined the efficacy of dupilumab in this at-risk patient population, and is the largest placebo-controlled study ever performed in uncontrolled, moderate-to-severe asthma with a biologic agent to date.

Rationale for Endpoint Choice {#Sec9}
-----------------------------

Annualized rate of severe exacerbation events is one of the most clinically relevant endpoints with which to evaluate asthma controller medications; by capturing this measure over a 52-week treatment period, any impact caused by seasonal variations in exacerbation rates was minimized. Absolute change from baseline in pre-bronchodilator FEV~1~ at week 12 was selected as the second primary endpoint; this is a well-accepted parameter to determine the effect of a drug on lung function, and is a predictor of mortality in asthma.

Rationale for Dose and Regimen {#Sec10}
------------------------------

In the phase 2b dose-ranging study \[[@CR9]\], both the 300 and 200 mg q2w dupilumab dose regimens provided better efficacy compared with the equivalent dupilumab dose regimens administered every 4 weeks on most efficacy endpoints, irrespective of eosinophil count at baseline. Both doses were well tolerated and (with the exception of an increased number of injection site reactions) had tolerability profiles comparable to those observed with placebo. Both regimens were assessed in the current trial to identify and further characterize the optimal dupilumab regimen in this patient population. Matching placebo arms were included to ensure the most robust assessment of the efficacy and safety of the dupilumab regimens.

There are currently limited treatment options for patients with uncontrolled, moderate-to-severe asthma. Add-on long-acting muscarinic receptor antagonists (tiotropium) \[[@CR10]\], and anti-IgE (omalizumab) \[[@CR11]\] and anti-IL-5 (reslizumab, mepolizumab, and benralizumab) \[[@CR12]--[@CR15]\] mAbs are all approved, and are added on to standard ICS plus LABA therapy, but are effective only in specific subgroups of patients. Omalizumab is indicated only for persistent asthma patients with a positive skin test or in vitro reactivity to a perennial aeroallergen \[[@CR16], [@CR17]\], and anti-IL-5 treatments have shown efficacy only in patients with eosinophilic asthma and are thus indicated for an eosinophilic phenotype \[[@CR18]--[@CR20]\].

Dupilumab is the first biologic to target both IL-4 and IL-13 type 2 cytokines and, as such, targets type 2 inflammation effectively, reducing not only eosinophil levels but also FeNO and periostin, two other type 2-associated biomarkers \[[@CR9]\]. The observation that dupilumab was efficacious in patients with baseline eosinophil levels of both \< 300 and ≥ 300 cells/μL in the phase 2b study was of particular interest, as prior to this, other biologics (such as the anti-IL-5 agents reslizumab, mepolizumab, and benralizumab) have shown that efficacy is limited to patients with eosinophilic asthma \[[@CR14], [@CR15], [@CR18]--[@CR20]\] and have been more effective in patients with higher baseline eosinophil levels. Such patients are typically associated with more severe asthma \[[@CR21]\]. A recently published phase 2 study of tezepelumab, a mAb specific for the epithelial-cell-derived cytokine thymic stromal lymphopoietin, in uncontrolled asthma has also shown efficacy irrespective of baseline eosinophil count \[[@CR22]\]. However, QUEST evaluates a biologic therapy for asthma with a trial design that facilitates entry into the study for all patients regardless of baseline eosinophil count, and is the first to assess the primary endpoint in the overall population, rather than a pre-specified eosinophil group. This is important, as it allows the adoption of a "real-world" approach to the treatment of asthma in a large patient population, thus ensuring that data are more representative of clinical practice. In addition, allowing patients the use of a third controller medicine if needed allows for a more accurate reflection of how patients are currently treated in clinical settings.

In terms of limitations of the QUEST study design, some of the subgroup analyses were not adequately powered. As such, any conclusions that may be drawn as a result of these analyses should be taken with caution until replicated with additional clinical trials.

Conclusions {#Sec11}
===========

QUEST was the largest phase 3 clinical trial to date to assess adults and adolescents (\> 12 years of age) with uncontrolled, moderate-to-severe asthma, despite treatment with ICS plus other controller medications, and to enroll patients irrespective of baseline eosinophil levels or any other biomarker requirement. The study aims to confirm earlier findings, and further demonstrate that dupilumab elicits responses in a broad range of patients with uncontrolled, moderate-to-severe asthma, and to provide these patients with improvements in lung function and asthma control, reductions in severe exacerbations, and an improved quality of life.
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